Cathay International Holdings Limited made an offer to acquire an additional 31.78% stake in Lansen Pharmaceutical Holdings Limited (SEHK:503) for HKD 240 million on September 8, 2023. The transaction will be financed from internal funds. The independent committee of the Board recommends the shareholders to vote in favor of the resolution. Completion is subject to approval by court, approval by shareholders of Lansen, regulatory approvals. Long stop date is April 30, 2024. Yu Ming Investment Management Limited acted as financial advisor to Cathay International and Altus Capital Limited acted as a financial advisor to Lansen. Link Market Services (Hong Kong) Pty Limited acted as registrar for Lansen.

Cathay International Holdings Limited completed the acquisition of additional 31.78% stake in Lansen Pharmaceutical Holdings Limited (SEHK:503) on December 15, 2023.